New Study Affirms Exergen Temporal Artery Thermometry (TAT) Is Accurate for Preterm Neonates
Apr 24, 2018 11:00 am UTC| Business
WATERTOWN, Mass., April 24, 2018 -- A new study published in the Journal of Obstetric, Gynecologic, Neonatal Nursing1 shows that Exergen temporal artery temperature measurements are as accurate as axillary temperature...
Inmar Consumer Drug Take-Back Program Now Operating in 32 States
Apr 24, 2018 11:00 am UTC| Business
Winston-Salem, NC, April 24, 2018 -- Winston-Salem, NC (April 25, 2018) – With the next National Prescription Take-Back Day taking place this Saturday, April 28, Inmar is reporting that their Consumer Drug Take-Back...
Astec Industries Reports First Quarter 2018 Results
Apr 24, 2018 11:00 am UTC| Business
CHATTANOOGA, Tenn., April 24, 2018 -- Astec Industries, Inc. (Nasdaq:ASTE) today reported results for their first quarter ended March 31, 2018. Net sales for the first quarter of 2018 were $325.5 million compared...
Apr 24, 2018 11:00 am UTC| Business
SAN RAMON, Calif., April 24, 2018 -- eQuest today announced the expansion of its interactive media group which will provide more significant services to its SMB and Enterprise customer base. The expansion will be phased...
Victory Capital to Announce First Quarter 2018 Results on May 8, 2018
Apr 24, 2018 11:00 am UTC| Business
CLEVELAND, April 24, 2018 -- Victory Capital Holdings, Inc. (NASDAQ:VCTR) (“Victory Capital” or the “Company”) today announced that it will report first quarter 2018 earnings results prior to the market open on Tuesday,...
CellAegis Announces First Distribution Agreement for autoRIC® in Europe
Apr 24, 2018 11:00 am UTC| Business
TORONTO, April 24, 2018 -- CellAegis Devices Inc. (“CellAegis”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular...
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018
Apr 24, 2018 11:00 am UTC| Business
SAN DIEGO and TORONTO, April 24, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying...